The technology involves a genetically engineered MCF-7 breast cancer cell line that has been modified to overexpress the Pin1 protein, a key peptidyl-prolyl cis/trans isomerase important for cell cycle regulation. These cells have been created using established genetic engineering techniques and are maintained as authenticated stocks to ensure consistent behavior in laboratory studies. This cell model facilitates detailed investigations into the cellular mechanisms governing breast cancer progression and provides a platform for screening compounds that might affect cell cycle dynamics.